MA-VALAMIS
24.9.2020 10:02:15 CEST | Business Wire | Press release
Valamis , the global leader in digital learning technologies and workforce development, published results from the “Global Survey on the State of Learning & Development (L&D) in the Workplace Report ,” which includes over 3000 people across more than 20 industries were surveyed from entry-level to C-Suite executives in organizations from Finland, France, Germany, Netherlands, Sweden, the US, and the UK.
Valamis conducted its 2nd annual “Global Survey on the State of Learning & Development (L&D) in the Workplace Report”, collecting insight into the shifting global priorities, challenges, behaviors, attitudes, and technologies in use for corporate learning and development, with additional research into the impact of COVID-19.
The importance of learning & development in the workforce
Findings from the survey show that roughly 93% of respondents globally believe updating knowledge and skills are important to an organization’s success and more than 50% of executives and the C-Suite value skills development as extremely important to an organization’s future success. Although the importance of learning and development has been recognized in every country surveyed, over 74% of respondents believe their organizations are actively encouraging the workforce to develop their skills and nearly 56% of respondents had a dedicated person or team responsible for learning and development at their organization.
Time to learn
Despite the globally acknowledged importance of learning and development, for the second consecutive year conducting the survey, the biggest challenge plaguing learning and development within organizations is a lack of time or perceived time affluence with regards to learning. 48% of respondents globally denoted a lack of time as the biggest challenge for learning and development. Interestingly, survey participants at the executive and C-suite level note that they use their digital learning environment the most frequently (Nearly 30% using it every day) of all survey participants.
Tools in place for corporate learning
25% of respondents specify not having the right tools in place as one of the top three challenges for learning & development. Approximately 15% of respondents demarcate that their organization does not have a digital learning environment in place at their organization, and the Netherlands has the highest percentage of respondents of all the countries surveyed that specify they have a Learning Management System (LMS) (24%) or Learning Experience Platform (LXP or LEP) (20%) in place, whereas the United States (28%), United Kingdom (29%), and Germany (28%) have the highest percentages of respondents relying on online courses or Massive Open Online Courses (MOOCs). Finland has the highest number of respondents (18%) that suggest their organization has no digital learning tools in place.
COVID-19 & L&D
Approximately 70% of executives within the global survey express they value digital learning and development more as a result of COVID-19, and over 67% of all global participants in the survey believe digital learning and development can help minimize the effects of shocks and stresses of future events.
“2020 has been a challenging year for many organizations and individuals worldwide. Our global survey on the state of learning and development highlights an internationally growing acknowledgment from the C-suite that L&D is critical to the success of their organizations, and with the right tools in place organizations can adapt and reskill in the face of unforeseen events,” said Janne Hietala, Chief Visionary Officer, Valamis.
Download the report here
.
*Please note the survey results are in English
About Valamis
Valamis is a digital learning company specializing in workforce development, and the developer of Valamis - Learning Experience Platform. Valamis' customers are large organizations spanning all industries—predominantly finance and insurance, complex manufacturing, and professional services. Headquartered in Joensuu, Finland, Valamis operates internationally with offices in the US, the UK, Germany, the Netherlands, Russia, and India.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200924005041/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
